Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Genomic characterization of metastatic breast cancers.
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F. Bertucci F, et al. Among authors: bachelot t. Nature. 2019 Aug;572(7767):E7. doi: 10.1038/s41586-019-1380-3. Nature. 2019. PMID: 31308536
Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.
Bertucci F, Borie N, Roche H, Bachelot T, Le Doussal JM, Macgrogan G, Debono S, Martinec A, Treilleux I, Finetti P, Esterni B, Extra JM, Geneve J, Hermitte F, Chabannon C, Jacquemier J, Martin AL, Longy M, Maraninchi D, Fert V, Birnbaum D, Viens P. Bertucci F, et al. Among authors: bachelot t. Breast Cancer Res Treat. 2011 Jun;127(2):363-73. doi: 10.1007/s10549-010-1003-z. Epub 2010 Jun 29. Breast Cancer Res Treat. 2011. PMID: 20585850
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C, Bidard FC. Pierga JY, et al. Among authors: bachelot t. Ann Oncol. 2012 Mar;23(3):618-624. doi: 10.1093/annonc/mdr263. Epub 2011 Jun 3. Ann Oncol. 2012. PMID: 21642515 Free article. Clinical Trial.
[Targeted chemotherapy for breast cancer: patients perception of the use of tumor gene profiling approaches to better adapt treatments].
Pellegrini I, Rapti M, Extra JM, Petri-Cal A, Apostolidis T, Ferrero JM, Bachelot T, Viens P, Bertucci F, Julian-Reynier C. Pellegrini I, et al. Among authors: bachelot t. Med Sci (Paris). 2012 Mar;28 Spec No 1:24-7. doi: 10.1051/medsci/2012281s107. Epub 2012 Apr 9. Med Sci (Paris). 2012. PMID: 22494653 Free article. Review. French.
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
Arnedos M, Scott V, Job B, De La Cruz J, Commo F, Mathieu MC, Wolp-Diniz R, Richon C, Campone M, Bachelot T, Dalenc F, Dessen P, Lacroix L, Lazar V, Soria JC, Delaloge S, Andre F. Arnedos M, et al. Among authors: bachelot t. Eur J Cancer. 2012 Oct;48(15):2293-9. doi: 10.1016/j.ejca.2012.06.014. Epub 2012 Jul 26. Eur J Cancer. 2012. PMID: 22840369
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C. Bachelot T, et al. Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub 2012 Nov 2. Lancet Oncol. 2013. PMID: 23122784 Clinical Trial.
332 results